Interaction between p12CDK2AP1 and a novel unnamed protein product inhibits cell proliferation by regulating the cell cycle

  • Authors:
    • Lijun Liu
    • Xiangming Yang
    • Qianwei Ni
    • Zhifeng Xiao
    • Yannan Zhao
    • Jin Han
    • Moyi Sun
    • Bing Chen
  • Corresponding author:
  • View Affiliations

  • Published online on: Friday, November 15, 2013
  • Pages: 156-162 DOI: 10.3892/mmr.2013.1801

Abstract

Human p12CDK2AP1 protein is encoded by the cyclin‑dependent kinase 2‑associated protein 1 (CDK2AP1) gene. This protein suppresses cell growth, differentiation and angiogenesis in numerous types of carcinoma by interacting with certain cell cycle proteins, including CDK2 and DNA polymerase α/primase. p12CDK2AP1 exerts its functions predominantly through protein‑protein interactions. Therefore, the identification of other p12CDK2AP1‑interacting proteins may clarify its role in cell cycle regulation and carcinogenesis. The aim of this study was to identify additional p12CDK2AP1‑interacting proteins. A novel unnamed protein product (UPP, BC006130) was identified through using a yeast two‑hybrid system. The interaction of p12CDK2AP1 with the UPP was further verified by glutathione S-transferase pull‑down and co‑immunoprecipitation experiments in vitro. The qPCR results following overexpression and siRNA assays demonstrated that the expression levels of the UPP were mediated by the CDK2AP1 gene. Furthermore, overexpression of the UPP gene was shown to shorten the length of the G2/M phase of the cell cycle in normal and tumor cell lines in a flow cytometry assay. The results of human tumor xenografts experiments in Balb/c nude mice indicated that stable transfection with the UPP gene was able to inhibit tumor cell proliferation in vivo. Overall, this study identified and characterized a novel interactive protein of p12CDK2AP1, which may inhibit cell proliferation by mediating the cell cycle. It expands the understanding of the mechanisms of p12CDK2AP1 and its potential as a cancer therapeutic target.

Introduction

Cyclin-dependent kinase 2-associated protein 1 (CDK2AP1) is a putative growth suppressor gene originally identified and isolated from normal keratinocytes (1). The human CDK2AP1 gene is 1.6 kb long and is located on chromosome 12q24.31 (2). The human and rodent polypeptides encoded by the CDK2AP1 gene share 97% identity, while the mouse and hamster sequences are identical (3). Human CDK2AP1 encodes a 115-amino acid peptide with a molecular mass of 12.4 kDa (pI 9.62), namely p12CDK2AP1(4). Previous studies have demonstrated that p12CDK2AP1 negatively regulates cell growth by sequestering the monomeric non-phosphorylated form of CDK2 and targeting it for proteolysis to reduce the active pool of CDK2 in cells (5). The protein also reduces CDK2-mediated retinoblastoma protein phosphorylation by reversing the activity of TGF-β (6). A previous study has demonstrated that miR-21 downregulates p12CDK2AP1 to stimulate cell proliferation and invasion (7). These observations indicate that p12CDK2AP1 acts as a growth suppressor through influencing mitosis, the S phase and the cell division cycle. A study has demonstrated that p12CDK2AP1 is also important in promoting Oct4 promoter methylation during murine embryonic stem cell differentiation and thereby downregulates Oct4 expression levels (8). In addition, p12CDK2AP1 has been shown to induce the epithelial-mesenchymal transition of hamster cheek pouch carcinoma-1 cells by promoting the expression of Twist2 (9).

Other clinical studies have demonstrated that p12CDK2AP1 is associated with oral squamous cell carcinoma, breast cancer, esophageal squamous cell carcinoma, gastric cancer and colorectal cancer (1014). It has also been identified that p12CDK2AP1 is involved in anti-angiogenesis modulation and the suppression of malignant biological interactions between prostate cancer and bone cells (15). The possibility of using p12CDK2AP1 as a therapeutic target has been suggested (16).

Proteins undertake numerous physiological functions, such as the regulation of enzymatic activities, the assembly of cellular components and signal transduction. The elucidation of protein-protein interactions (PPIs) and whole interaction networks is vital to understanding biophysical processes. It is well known that numerous types of cancer are caused by dysfunctions of certain protein interactions (17). Studies have demonstrated that a number of proteins interact with p12CDK2AP1(18,19). However, due to the diverse properties of proteins and the very different characteristics of PPIs (20), the proteins that interact with p12CDK2AP1 are not yet fully understood.

In the present study, a yeast two-hybrid assay was used to screen the proteins possibly interacting with p12CDK2AP1 and a novel unnamed protein product (UPP) was identified. The interaction between p12CDK2AP1 and this UPP was verified by glutathione S-transferase (GST) pull-down and co-immunoprecipitation (Co-IP) assays. Subsequently, the functions of the UPP in the PPIs with p12CDK2AP1 were studied in vitro and in vivo. The results demonstrated that p12CDK2AP1 regulates the expression of the UPP and may be inhibit cell proliferation by interaction with it.

Materials and methods

Materials

All chemicals were purchased from Sigma-Aldrich (St. Louis, MO, USA), unless otherwise mentioned. Dulbecco’s modified Eagle’s medium (DMEM), penicillin-streptomycin, Dulbecco’s phosphate-buffered saline (PBS) and fetal bovine serum (FBS) were purchased from Invitrogen (Carlsbad, CA, USA).

Yeast strain and growth medium

The genotypes of the Saccharomyces cerevisiae strain MaV203 (Invitrogen) used in this study were as follows: MATα, leu2-3, 112, trp1-901, his3Δ200, ade2-101, gal4Δ, gal80Δ SPAL10::URA3, GAL1::lacZ, HIS3UAS GAL1::HIS3@LYS2, can1R and cyh2R. This strain contains a set of non-reverting autotrophic mutations. A blend of yeast extract, peptone, dextrose and adenine sulfate medium was used to grow the untransformed yeast strain. Synthetic dropout minimal medium (Clontech Laboratories, Inc., Victoria, Australia) with appropriate nutrients was used to separate the untransformed yeast strain from the transformed.

Plasmid construction

Human liver CDK2AP1 cDNA (Stratagene, La Jolla, CA, USA) was ligated between the EcoR I and Xho I sites of a pBD-GAL4 Cam phagemid vector (Stratagene), downstream of the GAL4 DNA-binding domain. A liver cDNA library was digested by an interference-resistant helper phage from the Cam Phagemid Vector kit (Stratagene) and transformed into the Escherichia coli (E. coli) XLOLR strain (Stratagene). The human CDK2AP1 cDNA and the UPP gene were cloned into the pGEX-4T-1 GST fusion expression vector (GE Healthcare, Piscataway, NJ, USA). As there was no commercially available antibody to detect the UPP, HA and FLAG protein tags were used to identify the expression of the UPP and p12CDK2AP1. HA and FLAG mouse monoclonal antibodies (Zhongshan Golden-Bridge Biotechnology Co., Ltd., Beijing, China) were used to test the expression of HA-p12CDK2AP1 and FLAG-UPP in eukaryotes.

Yeast two-hybrid cDNA library screening assay

A human cDNA library was screened using the pBD-GAL4 plasmid, which was constructed with human full CDK2AP1 cDNA. The cDNA library bacterial XL1-Blue MRF was digested by a phage. The two vectors were then cotransfected into the MaV203 S. cerevisiae strain. Subsequently, positive clones were verified by distinguishing the His+ phenotype from the Leu+ and Try+ phenotypes. The screening procedure fully complied with the manufacturer’s instructions. Positive interaction was confirmed by testing the dropout culture media, and then the positive plasmid was transformed into E. coli JM109 for sequencing.

Pull-down assay

The pGEX 4T-p12CDK2AP1 and pGEX 4T-UPP plasmids were transformed into BL21 E. coli to express GST-p12CDK2AP1 and GST-UPP fusion proteins. Isopropyl β-D-1-thiogalactopyranoside (200 μl, 1 mM) was added to the flasks and the cells were induced for 5 h. The cells were then harvested with PBS. Pelleted cells were lysed by sonication in PBS and Complete Protease Inhibitor Cocktail (Roche, Mannheim, Germany). Following centrifugation at 12,000 × g for 5 min, the supernatants were applied to Glutathione Sepharose 4B (GE Healthcare). Thrombin Protease (GE Healthcare) was added to the GST-UPP tube for 30 min. The beads were pelleted, washed three times in PBS, resuspended in Laemmli sample buffer and analyzed by 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).

Cell culture and transfection

Human 293T cells and HeLa cells were cultured under 37°C, 5% CO2 in DMEM supplemented with 10% FBS, penicillin (10,000 U/ml) and streptomycin (10,000 μg/ml). When the cells reached 50–60% confluence, Lipofectamine 2000 reagent (Life Technologies Corp., Rockville, MD, USA) was used to transfect the pcDNA 3.1-FLAG-UPP and pcDNA 3.1-HA-p12CDK2AP1 plasmids according to the manufacturer’s instructions. The medium was changed after 5 h.

Co-IP and western blot analysis

A Protein G Immunoprecipitation kit was used to perform the Co-IP assay according to the instructions provided with the kit. The 293T cells were lysed in IP buffer 48 h after transfection. The lysate was divided into two spin columns and the samples were analyzed by SDS-PAGE. Proteins were transferred onto nitrocellulose membranes (Invitrogen) and then incubated with primary antibodies. The anti-HA antibody (1:10,000/2 μl) was applied to the UPP membrane, while the anti-FLAG antibody (1:10,000/2 μl) was applied to the p12CDK2AP1 membrane. After washing four times with TBST (20 mM Tris-HCl, pH 7.4; 137 mM NaCl and 0.1% (v/v) Tween 20), the membranes were incubated with horseradish peroxidase-conjugated goat anti-mouse secondary antibodies. The ECL Western Blotting Detection system (Amersham Biosciences, Piscataway, NJ, USA) was used to detect horseradish peroxidase on the immunoblots. The dried membranes were exposed to Carestream Kodak Biomax MR film for 2 min at room temperature.

siRNA and qPCR assays

The siRNA sequences used were designed and purchased from Genepharma Co. (Shanghai, China), and were as follows: Forward, 5′-UCUUUUCCAAACUGAAUGCGC-3′ and reverse, 5′-GCAUUCAGUUUGGAAAAGACA-3′ for the UPP gene; and forward, 5′-AGGAGAUCAGACCCACGUATT-3′ and reverse 5′-UACGUGGGUCUGAUCUCCUTT-3′ for the p12CDK2AP1 gene. The siRNA oligo was transfected into the 293T cell line with Lipofectamine 2000. After 24 h, the cells were harvested and divided into two centrifuge tubes. Total RNA from the cultured cells was isolated using TRIzol reagent (Life Technologies Corp., Carlsbad, CA, USA). The primers used to detect the expression levels were as follows: Forward, 5′-AACGGAACGGAATGC CAGATCCTA-3 and reverse, 5′-TTCAGAGCCAAGTGA ACCATGGGA-3′ for p12CDK2AP1; and forward, 5′-TGGTGC ACATCGTGTAACCTGTCT-3′ and reverse, 5′-AAGCTT TCCTTCCTCAGCCACTCT-3′ for the UPP. Following cDNA synthesis, qPCR was performed using the Bio-Rad Real-Time PCR Detection system (Bio-Rad, Hercules, CA, USA) with the human housekeeping cDNA GAPDH as the control. Radio immunoprecipitation assay buffer cocktail (Dingsheng Biotechnological Co., Beijing, China) was added to the tube containing 293T cells. Anti-mouse HA monoclonal antibody was used to perform western blotting to test the expression of p12CDK2AP1. The human 293T, A-549, HeLa, MCF-7, ACC-M, fibroblast and human mesenchymal stem cell lines were incubated to examine the endogenous expression of the p12CDK2AP1 and UPP genes. The comparative threshold cycle (CT) method was used to analyze relative changes in gene expression.

Flow cytometry and cell viability assay

The UPP-transfected 293T and HeLa cells were harvested at 12 and 24 h. Prior to flow cytometric examination, the cells were combined with propidium iodide (1 mg/ml) and RNase (50 μg/ml). The cell cycle was analyzed by flow cytometry (FACSCalibur; Becton-Dickinson, San Jose, CA, USA), and ModFit and CellQuest software was utilized. The plasmid pcDNA 3.1-FLAG-UPP was transfected into 293T cells. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (20 μl, 5 mg/ml) was applied to the wells after incubation for 24 h. Dimethyl sulfoxide (Amersco, Solon, OH, USA) was added to each well to dissolve the formazan crystals for 10 min. The samples were then transferred to a plate reader (ELx808; BioTek, Shanghai, China) and the absorbance at 570 nm was measured.

DNA methylation assay

The bisulfite sequencing PCR (BSP) method was used to examine the UPP gene promoter methylation in the 293T and HeLa cell lines. The methylation primers used to perform PCR were as follows: Forward, 5′-GTAGTG TGAGTGAGGGTTTTGATTT-3′ and reverse, 5′-CTAACA ACAAATTACCCCAACTTTC-3′. Streptozotocin buffer (Tris-HCl 10 mM, pH 8.0; EDTA 4 mM; NaCl 0.4 M), SDS and protease K were applied to harvested 293T and HeLa cells. DNA extraction followed the standard procedure. Na2S2O5 (5 mol/l) and hydroquinone mixture were used to prepare HeLa and 293T cell DNA. Subsequently, PCR was performed with the conditions as follows: 94°C for 5 min, 94°C for 40 sec, 56°C for 40 sec and 72°C for 50 sec for 34 cycles, and then 72°C for 10 min. An E.Z.N.A. Cycle Pure kit (Omega Bio-Tek Inc., Norcross, GA, USA) was used to purify the PCR products. Subsequently, the PCR products were ligated into a pMD 18T vector (Takara Bio, Inc., Tokyo, Japan) for sequencing. BiQ Analyzer software was used to statistically analyze the results (21).

Human tumor xenografts in vivo

The animal experiment followed the Laboratory Animal Center Institutional Animal Care and Use committee guidelines of the Peking University Health Science Center. Nude mice (n=36; Balb/c nude, female, four weeks old) were divided into three groups at random. The HeLa cells which were stably transfected with the UPP gene by an Overexpression Lentivector (SBI, Mountain View, CA, USA) were screened by flow cytometry. HeLa-UPP cells were subcutaneously injected at a density of 1×105 cells/ml into the armpits of the nude mice, with the HeLa cell line as the negative control and the blank plasmid-infected HeLa cells as the positive control. Once the tumors reached 3–5 mm, all the tumors were harvested. The weights and volumes of the tumors were then calculated at the same time.

Statistical analysis

All cell experiments were repeated three times. The data were calculated as the mean ± standard deviation and the statistical analyses were performed using SPSS Software, version 19.0 (SPSS, Inc., Chicago, IL, USA). The differences were considered to be statistically significant when P<0.05, as determined by Student’s t-test.

Results

Identification of a novel interaction protein of p12CDK2AP1 by a yeast two-hybrid screening assay

Interacting cellular partners of p12CDK2AP1 were searched for by screening a human cDNA library using a bait construct with the full CDK2AP1 cDNA cloned in-frame through using a yeast hybrid system. Following screening, positive clones were identified by selecting with synthetic dropout minimal medium. A protein that activated yeast transcription was detected (Fig. 1A). The activating domain/library plasmids were confirmed by the cotransformation procedure, and the nucleotide sequence of the protein was obtained by cloning and sequencing. Through blasting the sequence in the NCBI BLAST database, a novel protein named UPP (BC006130) was identified. The UPP is encoded by the Loc93622 gene, which is located on 4q16.1, and includes 119 amino acids.

Verification of the interaction between p12CDK2AP1 and the UPP in vitro

Considering the possibility of a false positive result in the yeast two-hybrid system, the interaction between p12CDK2AP1 and the UPP was confirmed by GST-pull down. The prokaryotic expression plasmids pGEX-4T-p12CDK2AP1 and pGEX-4T-UPP were constructed to express GST fusion proteins, and then the GST-p12CDK2AP1 and GST-UPP proteins were purified by GST affinity chromatography (Fig. 1B and C). Subsequently, the GST tag of GST-UPP was cleaved by thrombin protease. The pull-down result supports the specific interaction of p12CDK2AP1 with the UPP (Fig. 1D). To confirm this interaction in mammalian cells, the interaction of p12CDK2AP1 and the UPP was examined using a Co-IP assay. The bound proteins were detected by western blotting using antibodies which were specific to HA and FLAG (1E and F). These results demonstrated that p12CDK2AP1 interacts with the UPP in cells.

Expression and methylation of the UPP gene

To analyze the endogenous expression of the UPP gene, non-neoplastic cell lines (293T, human mesenchymal stem cells and human fibroblast cells) and human cancer cell lines (ACC-M, A-549, MCF-7 and HeLa) were tested. The results of the qPCR demonstrated that the UPP and p12CDK2AP1 were similarly expressed (Fig. 2A and B), that is, the UPP expression levels were higher in the non-neoplastic cell types than in cancer cell lines. Due to the high GC ratio (63%) of the UPP gene, the UPP gene was searched in the NCBI database and a CpG island of the gene was identified. The methylation of the UPP gene was investigated in the 293T and HeLa cell lines. The DNA of 293T and HeLa cells was extracted and amplified by BSP methods. The sequencing results demonstrated that there were 31 methylation sites in the UPP gene. In the DNA of the HeLa cells, all the methylation sites were methylated, while the 293T DNA was not methylated (Fig. 2C).

CDK2AP1 mediates expression of the UPP gene

To investigate the association between CDK2AP1 and the UPP gene, siRNA and overexpression assays were performed. Following transfection of the p12CDK2AP1 siRNA oligo, the western blot analysis demonstrated the silencing effect of the CDK2AP1 gene (Fig. 2D). The results indicated that the UPP expression levels were decreased when the CDK2AP1 gene was interfered with (Fig. 2E), while the UPP siRNA did not downregulate the expression levels of the CDK2AP1 gene (data not shown). Subsequently, the association between CDK2AP1 and the UPP was evaluated by overexpressing the two genes in the 293T cell line. The results revealed that overexpression of the CDK2AP1 gene significantly increases the expression levels of the UPP gene (Fig. 2F), while overexpression of the UPP gene does not affect the expression of CDK2AP1 (data not shown). Thus, the UPP may function as a downstream effector of CDK2AP1.

Overexpression of p12CDK2AP1 and UPP modulates the cell cycle and inhibits cell vitality in vitro

p12CDK2AP1 mediates the cell cycle and affects cell vitality; thus, whether the UPP gene also shifts the cell cycle and is associated with cell vitality was investigated. The UPP and p12CDK2AP1 genes were transfected into 293T and HeLa cells. After the genes had been transfected for 24 h, the flow cytometry data indicated that the percentage of cells in the G2/M phase was decreased significantly from 11.13% to 6.16% in the 293T cells (Fig. 3A) and from 12.15% to 7.65% in the HeLa cells (Fig. 3B). The cell growth curve demonstrated that overexpression of the UPP also suppresses cell proliferation (Fig. 3C and D). After transfection for 5 days, the cell vitality results indicated that overexpression of the UPP decreased cell survival (Fig. 3E and F).

Stably-transfected UPP inhibits the growth of human tumor xenografts in vivo

To investigate the mechanisms of action of the UPP protein in vivo, a HeLa cell line stably transfected with the UPP gene (Hela-UPP) was constructed (Fig. 4A and B) and transplanted in nude mice as xenografts. After 62 days, the xenograft tumors were harvested and fixed (Fig. 4C and D), and the weight and volume of the tumors were measured. The results demonstrated that the mean weight of the tumors of the HeLa-UPP cells (0.38±0.07 g) was lower than that of the control cells (0.77±0.11 g; Fig. 4E), and the mean volume of the tumors in the HeLa-UPP cells (109.62±20.40 mm3) was also lower than that of the control group (228.62±76.58 mm3; Fig. 4F). These results indicated that the UPP effectively inhibits the growth of human tumor xenografts.

Discussion

Mechanistic studies have demonstrated that p12CDK2AP1 binds to DNA polymerase α/primase protein, thereby inhibiting DNA replication (6). In addition, p12CDK2AP1 interacts with the monomeric non-phosphorylated form of the CDK2 protein to inhibit the S phase of the cell cycle (19). Thus, the PPIs of p12CDK2AP1 have a number of vital roles in physiological processes. However, the PPIs of p12CDK2AP1 require further study and the present study sought to identify proteins which interact with p12CDK2AP1.

Through using the two-hybrid system assay, a novel protein (UPP, BC006130) was identified to interact with p12CDK2AP1. The UPP is a 119-amino acid protein and its molecular mass is ~12.4 kDa. The protein is encoded by the Loc93622 gene, which is located on chromosome 4p16.1. Subsequently, the interaction was verified using pull-down and Co-IP assays. As the mechanism of the novel gene and protein has not been studied previously, the function of the protein was studied. To elucidate the association between the two genes, silencing and overexpressing assays were utilized. The results demonstrated that the expression of the UPP gene was mediated by the p12CDK2AP1 gene. However, the overexpression and silencing the UPP gene did not affect the expression of p12CDK2AP1. This indicated that the p12CDK2AP1 gene may regulate the expression of the UPP and, as the p12CDK2AP1 gene is a potent transcription repressor, the UPP gene may be located downstream of the p12CDK2AP1 gene. Subsequently, the endogenous expression of the UPP gene in different types of cell was detected. The expression of the UPP gene was observed to be higher in non-neoplastic cell lines than in cancer cell lines and, similar to the expression pattern of the p12CDK2AP1 gene, the expression of the UPP gene also demonstrated tissue specificity. This result also suggested that p12CDK2AP1 may mediate the expression of the UPP gene.

Two studies have demonstrated that the CDK2AP1 gene is a core subunit of the methyl CpG binding domain protein 2 and 3 NuRD complexes (MBD2/NuRD and MBD3/NuRD) (22,23). The CDK2AP1 gene is putatively associated with a methylated promoter as a component of the MBD2/NuRD complex and is associated with carcinogenesis. Therefore, the CDK2AP1 gene may be involved in epigenetic mechanisms. In the present study, the BSP method was used to examine the methylation of the Loc93622 gene in the 293T and HeLa cell lines. The results demonstrated that the gene is hypermethylated in HeLa cells, which explained why the expression levels of the Loc93622 gene were downregulated in the HeLa cells. The result also verified that the Loc93622 gene was methylated in certain cell lines in the UCSC Genome Bioinformatics database (http://genome.ucsc.edu/). While the homologs of the UPP, MORF4Ap1 and MORF4AP1L1 share sequence identity, they may have the similar function of interacting with histone acetylases and acetyltransferases to regulate chromatin dynamics (24). Further studies are required to address the association between the function of the CDK2AP1 gene and the Loc93622 gene methylation.

p12CDK2AP1 inhibits cancer cell proliferation through decreasing the length of the S phase of the cell cycle and it also changes the proportions of cells in the G1 and S phases. During carcinogenesis, the transcriptional function of the p12CDK2AP1-encoding gene (CDK2AP1) has been observed to be lost (25). Zolochevska et al(15) studied the CDK2AP1 mechanism in prostate cancer and they demonstrated that the gene inhibits cancer proliferation and changes the androgen-responsive pathway. In another study of the prostate cancer androgen receptor, it was identified that the UPP gene was upregulated in hormonal therapy-resistant prostate cancer (26). In the present study, overexpression of the UPP gene was performed to identify the functions of the UPP in the cell cycle. The results demonstrated that the length of the G2/M phase was decreased and that cell proliferation was suppressed. Moreover, the HeLa cells transfected with the UPP gene exhibited a lower tumorigenicity than the control in human tumor xenografts. As an interactive protein of p12CDK2AP1, the UPP may participate in the inhibition of cancer cell proliferation with p12CDK2AP1. This study speculated that p12CDK2AP1 not only controls S phase but also modulates the G2/M phase of the cell cycle by interacting with the UPP.

In conclusion, the present study demonstrated that the UPP is a novel binding protein of p12CDK2AP1. The interaction was verified by using in vitro and in vivo assays. Through studying the mechanisms of the interaction between the UPP and p12CDK2AP1, it was demonstrated that the expression of the UPP gene was regulated by the p12CDK2AP1 gene. Furthermore, p12CDK2AP1 may be involved in the methylation of the UPP gene promoter. The novel UPP inhibits tumor cell proliferation by regulating the cell cycle. These findings extend the understanding of the anticancer mechanism of p12CDK2AP1 in cancer therapy strategies.

Acknowledgements

This study was supported by grants from the National Natural Science Foundation of China (project no. 81072230) and the Ministry of Science and Technology of China (project no. 2010CB529403).

References

1 

Todd R, McBride J, Tsuji T, et al: Deleted in oral cancer-1 (doc-1), a novel oral tumor suppressor gene. FASEB J. 9:1362–1370. 1995.PubMed/NCBI

2 

Daigo Y, Suzuki K, Maruyama O, et al: Isolation, mapping and mutation analysis of a human cDNA homologous to the doc-1 gene of the Chinese hamster, a candidate tumor suppressor for oral cancer. Genes Chromosomes Cancer. 20:204–207. 1997. View Article : Google Scholar : PubMed/NCBI

3 

Tsuji T, Duh FM, Latif F, et al: Cloning, mapping, expression, function, and mutation analyses of the human ortholog of the hamster putative tumor suppressor gene Doc-1. J Biol Chem. 273:6704–6709. 1998. View Article : Google Scholar : PubMed/NCBI

4 

Kohno Y, Patel V, Kim Y, et al: Apoptosis, proliferation and p12(doc-1) profiles in normal, dysplastic and malignant squamous epithelium of the Syrian hamster cheek pouch model. Oral Oncol. 38:274–280. 2002. View Article : Google Scholar : PubMed/NCBI

5 

Rosenblatt J, Gu Y and Morgan DO: Human cyclin-dependent kinase 2 is activated during the S and G2 phases of the cell cycle and associates with cyclin A. Proc Natl Acad Sci USA. 89:2824–2828. 1992. View Article : Google Scholar : PubMed/NCBI

6 

Matsuo K, Shintani S, Tsuji T, et al: p12(DOC-1), a growth suppressor, associates with DNA polymerase alpha/primase. FASEB J. 14:1318–1324. 2000. View Article : Google Scholar : PubMed/NCBI

7 

Zheng J, Xue H, Wang T, et al: miR-21 downregulates the tumor suppressor P12 CDK2AP1 and stimulates cell proliferation and invasion. J Cell Biochem. 112:872–880. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Deshpande AM, Dai YS, Kim Y, et al: Cdk2ap1 is required for epigenetic silencing of Oct4 during murine embryonic stem cell differentiation. J Biol Chem. 284:6043–6047. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Tsuji T, Ibaragi S, Shima K, et al: Epithelial-mesenchymal transition induced by growth suppressor p12CDK2-AP1 promotes tumor cell local invasion but suppresses distant colony growth. Cancer Res. 68:10377–10386. 2008. View Article : Google Scholar : PubMed/NCBI

10 

Cwikla SJ, Tsuji T, McBride J, Wong DT and Todd R: doc-1-mediated apoptosis in malignant hamster oral keratinocytes. J Oral Maxillofac Surg. 58:406–414. 2000. View Article : Google Scholar : PubMed/NCBI

11 

Tao K, Fang M, Alroy J and Sahagian GG: Imagable 4T1 model for the study of late stage breast cancer. BMC Cancer. 8:2282008. View Article : Google Scholar : PubMed/NCBI

12 

Hiyoshi Y, Watanabe M, Hirashima K, et al: p12CDK2-AP1 is associated with tumor progression and a poor prognosis in esophageal squamous cell carcinoma. Oncol Rep. 22:35–39. 2009.PubMed/NCBI

13 

Choi MG, Sohn TS, Park SB, et al: Decreased expression of p12 is associated with more advanced tumor invasion in human gastric cancer tissues. Eur Surg Res. 42:223–229. 2009. View Article : Google Scholar : PubMed/NCBI

14 

Shin J, Yuan Z, Sreeramoju P, et al: A del T poly T (8) mutation in the 3′ untranslated region (UTR) of the CDK2-AP1 gene is functionally significant causing decreased mRNA stability resulting in decreased CDK2-AP1 expression in human microsatellite unstable (MSI) colorectal cancer (CRC). Surgery. 142:222–227. 2007.PubMed/NCBI

15 

Zolochevska O and Figueiredo ML: Cell-cycle regulators cdk2ap1 and bicalutamide suppress malignant biological interactions between prostate cancer and bone cells. Prostate. 71:353–367. 2011. View Article : Google Scholar

16 

Figueiredo ML, Kim Y, St John MA and Wong DT: p12CDK2-AP1 gene therapy strategy inhibits tumor growth in an in vivo mouse model of head and neck cancer. Clin Cancer Res. 11:3939–3948. 2005. View Article : Google Scholar : PubMed/NCBI

17 

Kar G, Gursoy A and Keskin O: Human cancer protein-protein interaction network: a structural perspective. PLoS Comput Biol. 5:e10006012009. View Article : Google Scholar : PubMed/NCBI

18 

Buajeeb W, Zhang X, Ohyama H, et al: Interaction of the CDK2-associated protein-1, p12(DOC-1/CDK2AP1), with its homolog, p14(DOC-1R). Biochem Biophys Res Commun. 315:998–1003. 2004. View Article : Google Scholar : PubMed/NCBI

19 

Shintani S, Ohyama H, Zhang X, et al: p12(DOC-1) is a novel cyclin-dependent kinase 2-associated protein. Mol Cell Biol. 20:6300–6307. 2000. View Article : Google Scholar : PubMed/NCBI

20 

Bonetta L: Protein-protein interactions: Interactome under construction. Nature. 468:851–854. 2010. View Article : Google Scholar : PubMed/NCBI

21 

Bock C, Reither S, Mikeska T, Paulsen M, Walter J and Lengauer T: BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. Bioinformatics. 21:4067–4068. 2005. View Article : Google Scholar : PubMed/NCBI

22 

Le Guezennec X, Vermeulen M, Brinkman AB, et al: MBD2/NuRD and MBD3/NuRD, two distinct complexes with different biochemical and functional properties. Mol Cell Biol. 26:843–851. 2006.PubMed/NCBI

23 

Spruijt CG, Bartels SJ, Brinkman AB, et al: CDK2AP1/DOC-1 is a bona fide subunit of the Mi-2/NuRD complex. Mol Biosyst. 6:1700–1706. 2010. View Article : Google Scholar : PubMed/NCBI

24 

Yochum GS and Ayer DE: Role for the mortality factors MORF4, MRGX, and MRG15 in transcriptional repression via associations with Pf1, mSin3A, and Transducin-Like Enhancer of Split. Mol Cell Biol. 22:7868–7876. 2002. View Article : Google Scholar

25 

Peng H, Shintani S, Kim Y and Wong DT: Loss of p12CDK2-AP1 expression in human oral squamous cell carcinoma with disrupted transforming growth factor-beta-Smad signaling pathway. Neoplasia. 8:1028–1036. 2006. View Article : Google Scholar : PubMed/NCBI

26 

Marques RB, Dits NF, Erkens-Schulze S, van Ijcken WF, van Weerden WM and Jenster G: Modulation of androgen receptor signaling in hormonal therapy-resistant prostate cancer cell lines. PLoS One. 6:e231442011. View Article : Google Scholar : PubMed/NCBI

Journal Cover

January 2014
Volume 9 Issue 1

Print ISSN: 1791-2997
Online ISSN:1791-3004

2014 Impact Factor: 1.554
Ranked #48/123 Medicine Research and Experimental
(total number of cites)

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Liu, L., Yang, X., Ni, Q., Xiao, Z., Zhao, Y., Han, J. ... Chen, B. (2014). Interaction between p12CDK2AP1 and a novel unnamed protein product inhibits cell proliferation by regulating the cell cycle. Molecular Medicine Reports, 9, 156-162. http://dx.doi.org/10.3892/mmr.2013.1801
MLA
Liu, L., Yang, X., Ni, Q., Xiao, Z., Zhao, Y., Han, J., Sun, M., Chen, B."Interaction between p12CDK2AP1 and a novel unnamed protein product inhibits cell proliferation by regulating the cell cycle". Molecular Medicine Reports 9.1 (2014): 156-162.
Chicago
Liu, L., Yang, X., Ni, Q., Xiao, Z., Zhao, Y., Han, J., Sun, M., Chen, B."Interaction between p12CDK2AP1 and a novel unnamed protein product inhibits cell proliferation by regulating the cell cycle". Molecular Medicine Reports 9, no. 1 (2014): 156-162. http://dx.doi.org/10.3892/mmr.2013.1801